Aquestive Therapeutics
AQST
152 hedge funds and large institutions have $369M invested in Aquestive Therapeutics in 2025 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 11 closing their positions.
336% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 11
134% more capital invested
Capital invested by funds: $158M → $369M (+$212M)
121% more call options, than puts
Call options by funds: $7.07M | Put options by funds: $3.21M
63% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 32
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
31% more funds holding
Funds holding: 116 → 152 (+36)
18.29% more ownership
Funds ownership: 47.95% → 66.24% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$27M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.3M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$10.8M |
| 4 |
PA
Perceptive Advisors
New York
|
+$6.79M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.31M |
| 2 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
-$6.85M |
| 3 |
Two Sigma Advisers
New York
|
-$1.83M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.35M |
| 5 |
EAM
Everstar Asset Management
Mooresville,
North Carolina
|
-$1.26M |
AQST Hedge Fund Activity: Q3 2025 in Review
152 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2025, worth a combined $369M — up 134% from $158M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new AQST positions and 11 closed out — a net gain of 37 holders — while 52 added to existing stakes and 32 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $27M. The largest seller was Millennium Management, cutting an estimated $7.31M.
- 152 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2025, up from 116 in Q2 2025.
- Funds reported $369M of Aquestive Therapeutics stock for Q3 2025, up 134% quarter-over-quarter.
- 48 funds opened new Aquestive Therapeutics positions in Q3 2025 and 11 closed out, a net change of +37 holders.
- The largest Aquestive Therapeutics buyer in Q3 2025 was RTW Investments, an estimated $27M added.
- The largest Aquestive Therapeutics seller in Q3 2025 was Millennium Management, an estimated $7.31M sold.
Based on aggregated 13F filings for Q3 2025.